← All tickers
MRK
Merck & Company, Inc.0 mentions · 0 source(s) · avg NaN
Live
—
—
bid —ask —
Waiting for trade ticks (off-hours: only bid/ask updates).
知名基金持仓
无知名基金持仓
Price
$118.72
-1.17 (-0.98%)
Day Range
118.19–120.67
52w Range
75.40–125.14
Mkt Cap
$293.22B
Sector
Healthcare
Next Earnings
2026-08-04
Fwd P/E
12.4
Beta
0.20
Implied Move · 2026-06-05 (6.5d)
±4.04% ($113.93–$123.51)
ATM IV 36%
Generating AI analysis…
源:大 V
暂无大 V 提及(签名尚未计算)
源:细分
共 35 条(过去 30 天)
- news32
- research3
题材
Keytruda & ADC PipelineKeytruda Combo TherapiesSac-TMT ADC PipelineOncology Clinical Trial Momentum
题材组
尚未归入题材组(签名缺失或提及不足)
SA 评级
更新于 23h agoQuant 评分
3.21
Hold
Wall St 共识
4.17
Buy
作者评级
4.00
Buy
作者评级分布(共 5 位)
SB 1B 3H 1S 0SS 0
Factor 评分
Growth
D-
F · A
Profit
A+
A+ · A+
Momentum
B
B+ · B
Value
D+
C+ · B-
Revisions
F
F · B+
下方两个 = 3M / 6M 前
季节性
暂无季节性数据
内部人交易 (180天)
180 天内无内部人交易
源:X 实时
实时数据暂不可用
Research · 3
Headlines · 15 from sa_press_release
- sa_press_release20hFDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
- seekingalpha_rss1dRegeneron, Gilead therapies eyed as potential Ebola treatments by WHO
- sa_press_release1dMerck Congratulates Ontario Government on Expanding Pharmacy Scope to Help Improve Access to Care
- seekingalpha_rssauthor:Brett Ashcroft Green1dBuilding A $100,000 All-Weather Dividend Portfolio For May 2026
- seekingalpha_rssauthor:Brett Ashcroft Green1dBuilding A $100,000 All-Weather Dividend Portfolio For May 2026
- sa_press_release1dMerck to Participate in the Jefferies Global Healthcare Conference
- seekingalpha_rssauthor:SA Transcripts2dMerck & Co., Inc. (MRK) Shareholder/Analyst Call - Slideshow
- seekingalpha_rssauthor:Baron Capital2dBaron Health Care Fund Q1 2026 Portfolio Activity
- sa_news3dMerck declares $0.85 dividend
- sa_press_release3dMerck Announces Third-Quarter 2026 Dividend
- sa_news7dSummit downgraded at H.C. Wainwright after Merck data for sac-TMT
- sa_news7dMerck and Kelun's lung cancer combo bests Keytruda in late-stage trial
- sa_press_release7dMerck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
- sa_press_release9dSynergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries
- sa_press_release9dSynergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries